HCW Biologics (HCW Biologics) Inventory-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. HCW Biologics's Average Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil. HCW Biologics's Revenue for the three months ended in Dec. 2023 was $1.32 Mil. HCW Biologics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.

HCW Biologics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 stayed the same from Sep. 2023 (0.00) to Sep. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. HCW Biologics's Days Inventory for the three months ended in Dec. 2023 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

HCW Biologics Inventory-to-Revenue Historical Data

The historical data trend for HCW Biologics's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics Inventory-to-Revenue Chart

HCW Biologics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

HCW Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventory-to-Revenue	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of HCW Biologics's Inventory-to-Revenue

For the Biotechnology subindustry, HCW Biologics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HCW Biologics's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where HCW Biologics's Inventory-to-Revenue falls into.

HCW Biologics Inventory-to-Revenue Calculation

HCW Biologics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (0	+	0)	/	1 )	/	2.842
=	0					/	2.842
=	0.00

HCW Biologics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (Q: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Revenue (Q: Dec. 2023 )
=	( (0	+	0)	/	1 )	/	1.324
=	0					/	1.324
=	0.00

HCW Biologics (NAS:HCWB) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

HCW Biologics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	0	/	1.071	*	365 / 4
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

HCW Biologics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	1.071	/	0
	=

HCW Biologics Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of HCW Biologics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

HCW Biologics (HCW Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 N Commerce Parkway, Miramar, FL, USA, 33025

Website

https://www.hcwbiologics.com

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company believes age-related low-grade chronic inflammation is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases.

Executives

Gary M Winer	director	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong	director, officer: Chief Executive Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam	officer: Chief Financial Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers	officer: SVP of Business Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene	director	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao	officer: VP of Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett	director	35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode	officer: See Remarks	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd.	10 percent owner	16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057